Innate Pharma competitive analysis

Explore Innate Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 10, 2026
Patent NumberPublication DateTitleTotal Oppositions
Aug 13, 2025Neutralization Of Inhibitory Pathways In Lymphocytes1
Dec 11, 2024Treatment Of Cancer2
Jun 7, 2023Monoclonal Antibodies Against Nkg2A1
Feb 24, 2021Neutralization Of Inhibitory Pathways In Lymphocytes2
Nov 4, 2020Cross Reactive Siglec Antibodies1
Oct 7, 2015Monoclonal Antibodies Against Nkg2A1

Latest PTAB cases involving Innate Pharma

Discover the latest PTAB cases involving Innate Pharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Innate Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
INNATE PHARMA - 7 - -
ARROWHOUSE12 - - -
MERCK SHARP & DOHME2656615
STRAWMAN471 - - -